Name | Alvelestat |
Description | Alvelestat (AZD9668) is an orally bioavailable, selective, and reversible inhibitor of human neutrophil elastase (NE), exhibiting potential anti-inflammatory activity. |
In vitro | In a mouse model of (smoke)-induced airway inflammation, AZD9668 significantly reduced the number of (neutrophils) in the bronchoalveolar lavage (BAL) and the level of BAL IL-1β. Oral administration of AZD9668 in both mice and rats was able to inhibit (NE)-induced lung injury. |
In vivo | In whole blood stimulated by yeast polysaccharide, AZD9668 effectively inhibits NE (NE) activity in the supernatant of antigen-challenged cells and on the surface of stimulated polymorphonuclear cells. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 40 mg/mL (73.32 mM)
|
Keywords | Elastase | AZD 9668 | Inhibitor | AZD-9668 | inhibit | Alvelestat |
Inhibitors Related | PMSF | Nafamostat mesylate | Diminazene Aceturate | AEBSF hydrochloride | 2-(2-bromophenyl)-5-chloro-4H-3,1-benzoxazin-4-one | Leupeptin Hemisulfate | Ceritinib | Aprotinin | Sivelestat | 4-Aminobenzamidine dihydrochloride | 2,4-Dioxaspiro(5.5)undec-8-ene, 3-(2-furanyl)- | Benzamidine hydrochloride |
Related Compound Libraries | Highly Selective Inhibitor Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Inhibitor Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Human Metabolite Library |